GCP
DFTX

GSA Capital Partners’s Definium Therapeutics DFTX Stock Holding History

GSA Capital Partners’s Portfolio DFTX Stock Details DFTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$343K Sell
18,155
-34,100
-65% -$579K 0.02% 1168
2025
Q4 		$700K Sell
52,255
-3,234
-6% -$40K 0.06% 588
2025
Q3 		$654K Buy
+55,489
New +$517K 0.05% 672

Other funds holding DFTX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

GSA Capital Partners's DFTX Position: Q1 2026 in Review

GSA Capital Partners reduced its Definium Therapeutics (DFTX) stake by 65% in Q1 2026, selling an estimated $579K and leaving 18,155 shares worth $343K. The position accounts for 0.02% of the portfolio, ranked #1168.

GSA Capital Partners first reported a position in DFTX in Q3 2025 and has held it in 3 quarters since. The position peaked at $700K in Q4 2025. 247 funds tracked by Wall St. Rank hold DFTX as of Q1 2026.

  • GSA Capital Partners held 18,155 shares of Definium Therapeutics worth $343K as of Q1 2026.
  • GSA Capital Partners sold 34,100 Definium Therapeutics shares in Q1 2026, an estimated $579K.
  • Definium Therapeutics made up 0.02% of GSA Capital Partners's portfolio in Q1 2026, its #1168 holding.
  • GSA Capital Partners first reported a position in Definium Therapeutics in Q3 2025 and has held it in 3 quarters since.
  • GSA Capital Partners's Definium Therapeutics position peaked at $700K in Q4 2025.
  • 247 funds tracked by Wall St. Rank held Definium Therapeutics as of Q1 2026.

Based on GSA Capital Partners's 13F filing for Q1 2026, filed 8 May 2026.